Description
The National Heart, Lung, and Blood Institute (NHLBI) will sole‑source a purchase order to Vanderbilt University Medical Center to perform a targeted Clonal Hematopoiesis of Indeterminate Potential (CHIP) sequencing assay on 11,000 samples. The work supports the Framingham Heart Study by replicating prior whole‑genome sequencing results using an orthogonal assay developed by the BICK Lab. The contractor will access FHS and whole‑genome sequencing data, run the targeted assay, perform statistical analyses, and transfer all data to NIH via Google Cloud. Collaboration with NHLBI intramural scientists is required, and final deliverables include comprehensive statistical reports.
• Location: Vanderbilt University Medical Center, Nashville, TN
• Duration: 12‑month base period
• Scope: Sample processing (11,000), targeted sequencing, data analysis, cloud data transfer, reporting
• Funding ceiling: $19.5 M (small‑business set‑aside)
• Sole‑source justification: Unique assay technology resides only in VUMC’s BICK Lab
• Submission deadline: 09/14/2026 10:00 am EDT